Fidia Announces US Commercial Availability of Hymovis®, a Next-Generation Hyaluronan

A breakthrough in viscoelastic technology; Hymovis® is an excellent choice for the high-demand patient with OA of the knee

PARSIPPANY, N.J., May 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., announced that Hymovis® (high molecular weight viscoelastic hyaluronan) is now commercially available in the U.S.

Hymovis® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties, and results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows the molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked Hymovis® has increased elasticity, viscosity and residence time in the joint.

Fidia Pharma USA Inc. has partnered with Henry Schein® and Besse® Medical for distribution of Hymovis®. Ordering can take place online at www.henryschein.com and www.besse.com. There are low thresholds for contract pricing and no minimum quantity is required.

For patient specific insurance verifications or general Hymovis® product and reimbursement information, please call 1-866-HYMOVIS or visit www.hymovis.com. For Hymovis® billing and coding, use J3490 in the Physician/Office setting; C9472 in the Hospital Outpatient/Ambulatory Surgical Center and CPT 20619 or 20611.

Hymovis® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

About Fidia Pharma USA Inc.

Fidia Pharma USA Inc is a wholly-owned subsidiary of Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid market segment.
Fidia Pharma USA Inc. is focused on expanding Fidia's position in the U.S. and Canadian market, while upholding the company's mission to provide consumers with innovative products that offer quality, safety and performance. Fidia Pharma USA Inc. is headquartered in Parsippany, NJ.
For more information, please visit www.fidiapharma.us.

About Fidia Farmaceutici S.p.A.

Fidia Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1946. It is a leader in research and marketing hyaluronic acid-based products, with several applications in the biomedical field, such as rheumatology, orthopaedics, surgery, wound care, tissue repair and dermo-aesthetics. Fidia Farmaceutici is part of the P&R Holding group. The company is located in Italy, with R&D facilities in Abano Terme (Padua) and Noto (Sicily). Fidia has more than 700 employees, and its revenue exceeds €250 million euros. Fidia Farmaceutici S.p.A.'s products are marketed in more than

100 countries, through wholly owned subsidiaries and a comprehensive network of international partnerships and distributors.Thanks to its investment in research, it has created a legacy of products with more than 600 patents to its name. For more information, please visit www.fidiapharma.com.

For more information, contact:
Fidia Pharma USA Inc.
Morris Corporate Center 1
Building C, 1st floor
300 Interpace Parkway
Parsippany, NJ 07054
1-973-507-5120
ckong@fidiapharma.us

Indication
Hymovis® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

Important Safety Information
Hymovis® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram positive bacterial proteins. Do not administer Hymovis® to patients with infections or skin diseases in the area of the injection site or joint.

The safety and effectiveness of the use of Hymovis® has not been tested in pregnant women, nursing mothers or children. The safety and effectiveness of the use of Hymovis® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections has not been established. The effectiveness of repeat treatment cycles of Hymovis® has not been established. Arthralgia, transient pain or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for Hymovis® was equivalent to the control group. No serious adverse reactions or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

Rx Only

###